An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers.
Immunoscore
Macrophages
Tumour immunology
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
29
08
2022
revised:
21
12
2022
accepted:
11
01
2023
pubmed:
2
2
2023
medline:
15
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
Cancer immunity is based on the interaction of a multitude of cells in the spatial context of the tumour tissue. Clinically relevant immune signatures are therefore anticipated to fundamentally improve the accuracy in predicting disease progression. Through a multiplex in situ analysis we evaluated 15 immune cell classes in 1481 tumour samples. Single-cell and bulk RNAseq data sets were used for functional analysis and validation of prognostic and predictive associations. By combining the prognostic information of anti-tumoural CD8 Our findings extend current concepts to procure prognostic information from the tumour immune microenvironment and provide an immune activation signature with high clinical potential in common human cancer types. Swedish Cancer Society, Lions Cancer Foundation, Selanders Foundation, P.O. Zetterling Foundation, U-CAN supported by SRA CancerUU, Uppsala University and Region Uppsala.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer immunity is based on the interaction of a multitude of cells in the spatial context of the tumour tissue. Clinically relevant immune signatures are therefore anticipated to fundamentally improve the accuracy in predicting disease progression.
METHODS
METHODS
Through a multiplex in situ analysis we evaluated 15 immune cell classes in 1481 tumour samples. Single-cell and bulk RNAseq data sets were used for functional analysis and validation of prognostic and predictive associations.
FINDINGS
RESULTS
By combining the prognostic information of anti-tumoural CD8
INTERPRETATION
CONCLUSIONS
Our findings extend current concepts to procure prognostic information from the tumour immune microenvironment and provide an immune activation signature with high clinical potential in common human cancer types.
FUNDING
BACKGROUND
Swedish Cancer Society, Lions Cancer Foundation, Selanders Foundation, P.O. Zetterling Foundation, U-CAN supported by SRA CancerUU, Uppsala University and Region Uppsala.
Identifiants
pubmed: 36724681
pii: S2352-3964(23)00017-8
doi: 10.1016/j.ebiom.2023.104452
pmc: PMC9918750
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104452Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A.M. and T.S. are co-inventors on a provisional patent application P42105124SE00 “Novel biomarker” regarding a method for the prognosis of survival time of a subject diagnosed with a cancer described herein. K.L. is a board member of Cantargia AB, a company developing IL1RAP inhibitors. This does not alter the Author's adherence to all guidelines for publication. No other funding except listed in the section Methods/Funders was involved. No other conflicts of interest were disclosed by the other authors.
Références
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Stat Med. 2013 Dec 30;32(30):5381-97
pubmed: 24027076
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Nat Genet. 2020 Jun;52(6):594-603
pubmed: 32451460
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Clin Cancer Res. 2019 Jul 1;25(13):3896-3907
pubmed: 30988081
Clin Chem. 2019 Oct;65(10):1228-1238
pubmed: 31315901
Front Immunol. 2019 Aug 30;10:2035
pubmed: 31543877
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Immunol. 2002 Oct 1;169(7):3978-86
pubmed: 12244199
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Nat Cell Biol. 2014 Aug;16(8):717-27
pubmed: 25082194
Gut. 2020 Apr;69(4):681-690
pubmed: 31780575
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Oncotarget. 2016 Aug 2;7(31):49322-49333
pubmed: 27384994
JAMA. 2014 Nov 5;312(17):1744-53
pubmed: 25369488
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Biometrics. 2005 Mar;61(1):92-105
pubmed: 15737082
Sci Rep. 2020 Jan 14;10(1):281
pubmed: 31937798
Annu Rev Immunol. 2015;33:643-75
pubmed: 25861979
Oncotarget. 2018 Jan 02;9(22):16213-16219
pubmed: 29662638
Sci Rep. 2016 Nov 02;6:36149
pubmed: 27805003
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Sci Rep. 2021 Mar 15;11(1):6047
pubmed: 33723286
Acta Oncol. 2018 Feb;57(2):187-194
pubmed: 28631533
Science. 2013 Jan 18;339(6117):286-91
pubmed: 23329041
EBioMedicine. 2021 Mar;65:103269
pubmed: 33706249
J Ovarian Res. 2010 Jun 17;3:14
pubmed: 20565760
Front Oncol. 2019 Mar 13;9:136
pubmed: 30931254
Clin Cancer Res. 2022 Apr 14;28(8):1479-1481
pubmed: 35121621
J Immunol. 2012 Jun 1;188(11):5682-93
pubmed: 22523386
Cancer Immunol Res. 2018 Apr;6(4):481-493
pubmed: 29467127
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Nat Commun. 2016 Feb 01;7:10346
pubmed: 26831747
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Cancer Immunol Res. 2021 Jan;9(1):8-19
pubmed: 33023967
Nat Commun. 2020 Jan 24;11(1):496
pubmed: 31980621
Cancer Immunol Res. 2016 Apr;4(4):269-78
pubmed: 27036971
Invest New Drugs. 2013 Jun;31(3):760-8
pubmed: 22907596
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
Science. 2018 May 4;360(6388):558-563
pubmed: 29724957
J Thorac Oncol. 2016 Jun;11(6):862-72
pubmed: 26872818
Lancet. 2019 Aug 10;394(10197):478-487
pubmed: 31229240
Sci Rep. 2019 Dec 27;9(1):19997
pubmed: 31882709
Cancer Res. 2016 Nov 15;76(22):6439-6442
pubmed: 28148676
J Immunol. 1991 Dec 1;147(11):3988-93
pubmed: 1940381
Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):351-357
pubmed: 29681201
Nat Rev Immunol. 2009 Apr;9(4):259-70
pubmed: 19282852
Cancer Cell. 2021 May 10;39(5):649-661.e5
pubmed: 33711272
Front Immunol. 2020 Sep 10;11:558169
pubmed: 33013928
Oncoimmunology. 2015 Oct 29;5(4):e1101204
pubmed: 27141383
Mol Immunol. 2010 Jul;47(11-12):2129-37
pubmed: 20417969
Gynecol Oncol. 2015 Jun;137(3):529-37
pubmed: 25858696
Br J Cancer. 2014 Sep 9;111(6):1180-7
pubmed: 25072257
Front Med (Lausanne). 2015 May 26;2:33
pubmed: 26131447
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Gynecol Oncol. 2018 Apr;149(1):173-180
pubmed: 29486992
Clin Cancer Res. 2020 Jan 15;26(2):332-339
pubmed: 31413009
J Pathol. 2018 Apr;244(4):421-431
pubmed: 29282718
Int J Cancer. 2016 Sep 1;139(5):1129-39
pubmed: 27074317
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Neuro Oncol. 2016 Apr;18(4):557-64
pubmed: 26449250
Front Immunol. 2019 Jul 17;10:1642
pubmed: 31379841
J Immunol. 2000 Jun 15;164(12):6166-73
pubmed: 10843666
Clin Cancer Res. 2015 Apr 15;21(8):1843-50
pubmed: 25628399
Oncotarget. 2017 Jul 21;8(42):72108-72126
pubmed: 29069772
EBioMedicine. 2016 Apr;6:50-58
pubmed: 27211548
Biomark Res. 2014 Jan 07;2(1):1
pubmed: 24398220
Int J Cancer. 2020 Jun 15;146(12):3461-3473
pubmed: 32129882
Genome Biol. 2020 Dec 7;21(1):294
pubmed: 33287869
Sci Rep. 2021 Apr 15;11(1):8282
pubmed: 33859282
Nat Rev Immunol. 2017 Jun;17(6):349-362
pubmed: 28436425
Cancer Res. 1987 May 1;47(9):2474-80
pubmed: 3552215
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Immunity. 2018 Oct 16;49(4):595-613
pubmed: 30332628
JAMA Oncol. 2019 Aug 01;5(8):1195-1204
pubmed: 31318407
Front Oncol. 2020 Oct 23;10:534761
pubmed: 33194593
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643229
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
J Proteome Res. 2009 Apr;8(4):1639-46
pubmed: 19714869